BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 2020;135:472-90. [PMID: 31756253 DOI: 10.1182/blood.2019003599] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Pizzi M, Friziero A, Vianello F, Binotto G, Da Dalt G, Zoletto S, Carraro E, Fassan M, Sbaraglia M, Sperti C, Baldan N, D'Amore F, Bertozzi I, Righi S, Pierobon ES, Moletta L, Capovilla G, Grego A, Sabattini E, Fabris F, Merigliano S, Dei Tos AP. Histology of the spleen in immune thrombocytopenia: clinical-pathological characterization and prognostic implications. Eur J Haematol 2021;106:281-9. [PMID: 33190299 DOI: 10.1111/ejh.13547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dierickx D, Neefs J. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients. Expert Opin Pharmacother 2022. [PMID: 35621338 DOI: 10.1080/14656566.2022.2082283] [Reference Citation Analysis]
3 von Hundelshausen P, Siess W. Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. Cancers (Basel) 2021;13:1103. [PMID: 33806595 DOI: 10.3390/cancers13051103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Sun Y, Long S, Liu W. Risk Factors and Psychological Analysis of Chronic Immune Thrombocytopenia in Children. Int J Gen Med 2020;13:1675-83. [PMID: 33408505 DOI: 10.2147/IJGM.S290459] [Reference Citation Analysis]
5 Song AB, Al-Samkari H. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia. Expert Rev Clin Immunol 2022. [PMID: 35793401 DOI: 10.1080/1744666X.2022.2098119] [Reference Citation Analysis]
6 Gómez-Almaguer D, Rojas-Guerrero EA, Gómez-De León A, Colunga-Pedraza PR, Jaime-Pérez JC. Alternatives for managing patients with newly diagnosed immune thrombocytopenia: a narrative review. Expert Rev Hematol 2022. [PMID: 35615916 DOI: 10.1080/17474086.2022.2082936] [Reference Citation Analysis]
7 Koilpillai S, Dominguez B, Khan A, Carlan S. Severe case of refractory immune thrombocytopenic purpura requiring splenectomy after the COVID-19 vaccine. BMJ Case Rep 2022;15:e250153. [PMID: 35725277 DOI: 10.1136/bcr-2022-250153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Bonnard G, Babuty A, Collot R, Costes D, Drillaud N, Eveillard M, Néel A, Espitia A, Masseau A, Wahbi A, Hamidou M, Béné MC, Fouassier M. Platelet features allow to differentiate immune thrombocytopenia from inherited thrombocytopenia. Ann Hematol 2021;100:2677-82. [PMID: 34519886 DOI: 10.1007/s00277-021-04651-4] [Reference Citation Analysis]
9 Nomura S, Abe M, Yamaoka M, Ito T. Effect of Cytokine Gene Polymorphisms on Eltrombopag Reactivity in Japanese Patients with Immune Thrombocytopenia. J Blood Med 2021;12:421-9. [PMID: 34113203 DOI: 10.2147/JBM.S309680] [Reference Citation Analysis]
10 Li C, Li L, Sun M, Sun J, Shao L, Xu M, Hou Y, Peng J, Wang L, Hou M. Predictive Value of High ICAM-1 Level for Poor Treatment Response to Low-Dose Decitabine in Adult Corticosteroid Resistant ITP Patients. Front Immunol 2021;12:689663. [PMID: 34326842 DOI: 10.3389/fimmu.2021.689663] [Reference Citation Analysis]
11 Song F, Al-Samkari H. Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice. J Blood Med 2021;12:653-64. [PMID: 34345191 DOI: 10.2147/JBM.S259101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sun L, Wang J, Shao L, Yuan C, Zhao H, Li D, Wang Z, Han P, Yu Y, Xu M, Zhao H, Qiu J, Zhou H, Liu X, Hou Y, Peng J, Hou M. Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol 2021;8:e289-98. [PMID: 33770484 DOI: 10.1016/S2352-3026(21)00030-2] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Shragai T, Lebel E, Deshet D, Varon D, Avivi I, Kirgner I, Sarid N. Characteristics and outcomes of adults with cytomegalovirus‐associated thrombocytopenia: a case series and literature review. Br J Haematol 2020;191:863-7. [DOI: 10.1111/bjh.17017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Gudbrandsdottir S, Leven E, Imahiyerobo A, Lee CS, Bussel J. Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children. Br J Haematol 2020;189:e37-40. [PMID: 32096213 DOI: 10.1111/bjh.16426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Wada H, Ichikawa Y, Ezaki M, Shiraki K, Moritani I, Yamashita Y, Matsumoto T, Masuya M, Tawara I, Shimpo H, Shimaoka M. Clot Waveform Analysis Demonstrates Low Blood Coagulation Ability in Patients with Idiopathic Thrombocytopenic Purpura. J Clin Med 2021;10:5987. [PMID: 34945283 DOI: 10.3390/jcm10245987] [Reference Citation Analysis]
16 Ni X, Li D, Yuan C, Yu Y, Wang H, Wang L, Yu T, Qin P, Peng J, Hou M, Shi Y, Hou Y. Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: A multicenter, randomized, controlled study. Am J Hematol 2022;97:440-7. [PMID: 35049070 DOI: 10.1002/ajh.26473] [Reference Citation Analysis]
17 Gordon MJ, Ferrajoli A. Unusual complications in the management of chronic lymphocytic leukemia. Am J Hematol 2022. [PMID: 35491515 DOI: 10.1002/ajh.26585] [Reference Citation Analysis]
18 Han P, Yu T, Hou Y, Zhao Y, Liu Y, Sun Y, Wang H, Xu P, Li G, Sun T, Hu X, Liu X, Li L, Peng J, Zhou H, Hou M. Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction via Modulating PD-1 Methylation in Immune Thrombocytopenia. Front Immunol 2021;12:630693. [PMID: 33679776 DOI: 10.3389/fimmu.2021.630693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Lee EJ, Bussel JB. An "ATRA-ctive" new treatment of ITP? Blood 2022;139:307-8. [PMID: 35050337 DOI: 10.1182/blood.2021014490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Mahévas M, Audia S, Viallard JF. [Management of multirefractory immune thrombocytopenia]. Rev Med Interne 2021;42:46-9. [PMID: 33334631 DOI: 10.1016/j.revmed.2020.10.378] [Reference Citation Analysis]
21 Fu L, Ma J, Gu H, Ma J, Wei Y, Chen Z, Wu R. An escalating treatment strategy for children with severe chronic immune thrombocytopenia: Preliminary report from a single center. Pediatr Blood Cancer 2021;68:e29006. [PMID: 33720524 DOI: 10.1002/pbc.29006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Saito M, Morioka M, Izumiyama K, Mori A, Kondo T. Severe Portal Vein Thrombosis During Eltrombopag Treatment Concomitant Splenectomy for Immune Thrombocytopenia. Cureus 2021;13:e17478. [PMID: 34589366 DOI: 10.7759/cureus.17478] [Reference Citation Analysis]
23 Choy J, Swe EPP, Shearer A. Amifostine and rituximab in refractory immune thrombocytopaenia: A case series. Vox Sang 2021. [PMID: 34939200 DOI: 10.1111/vox.13226] [Reference Citation Analysis]
24 Tsykunova G, Ghanima W. Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives. Ther Clin Risk Manag 2022;18:273-86. [PMID: 35386180 DOI: 10.2147/TCRM.S251672] [Reference Citation Analysis]
25 Kyrle PA, Eichinger S. How I manage cyclic thrombocytopenia. Blood 2021;137:178-84. [PMID: 33197928 DOI: 10.1182/blood.2020008218] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Hicks SM, Lee CSM, Ali SA, Choi PY, Gardiner EE. The molecular basis of immune-based platelet disorders. Clin Sci (Lond) 2020;134:2807-22. [PMID: 33140828 DOI: 10.1042/CS20191101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Jolink AC, Nelson VS, Schipperus MR, Amini SN, Vidarsson G, van der Schoot CE, Porcelijn L, de Haas M, Kapur R. Potential Diagnostic Approaches for Prediction of Therapeutic Responses in Immune Thrombocytopenia. J Clin Med 2021;10:3403. [PMID: 34362187 DOI: 10.3390/jcm10153403] [Reference Citation Analysis]
28 Xu L, Zhang Y, Lin N, Song X, Dai Q. Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome. Science Progress 2022;105:003685042211027. [DOI: 10.1177/00368504221102786] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Li C, Sun M, Li R, Wang S, Shao L, Xu M, Yao M, Wang L, Hou M, Feng Q, Peng J. Association of metformin treatment and outcome in adult patients with ITP and pre-existing T2DM. Br J Haematol 2022. [PMID: 35288929 DOI: 10.1111/bjh.18121] [Reference Citation Analysis]
30 Janssens A, Selleslag D, Depaus J, Beguin Y, Lambert C. Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society. Acta Clin Belg 2022;77:470-83. [PMID: 33635747 DOI: 10.1080/17843286.2021.1876310] [Reference Citation Analysis]
31 Althaus K, Faul C, Bakchoul T. New Developments in the Pathophysiology and Management of Primary Immune Thrombocytopenia. Hamostaseologie 2021;41:275-82. [PMID: 33348391 DOI: 10.1055/a-1311-8264] [Reference Citation Analysis]
32 Zhao Y, Xu P, Guo L, Wang H, Min Y, Feng Q, Hou Y, Sun T, Li G, Ji X, Qiu J, Peng J, Liu X, Hou M. Tumor Necrosis Factor-α Blockade Corrects Monocyte/Macrophage Imbalance in Primary Immune Thrombocytopenia. Thromb Haemost 2021;121:767-81. [PMID: 33469903 DOI: 10.1055/s-0040-1722186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Kapur R. Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists. Br J Haematol 2022. [PMID: 35748239 DOI: 10.1111/bjh.18332] [Reference Citation Analysis]
34 Xu P, Zhao Y, Yu T, Yu Y, Ni X, Wang H, Sun L, Han P, Wang L, Sun T, Liu X, Zhou H, Peng J, Hou M, Hou Y, Xu M. Atorvastatin restores imbalance of cluster of differentiation 4 (CD4)+ T cells in immune thrombocytopenia in vivo and in vitro. Br J Haematol 2021. [PMID: 34825359 DOI: 10.1111/bjh.17938] [Reference Citation Analysis]
35 Ji L, Cheng Y. Treg cell abnormality and its potential treatments in patients with primary immune thrombocytopenia. Clinical and Translational Dis 2022;2. [DOI: 10.1002/ctd2.77] [Reference Citation Analysis]
36 Vianelli N, Auteri G, Buccisano F, Carrai V, Baldacci E, Clissa C, Bartoletti D, Giuffrida G, Magro D, Rivolti E, Esposito D, Podda GM, Palandri F. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. Ann Hematol 2022. [PMID: 35201417 DOI: 10.1007/s00277-022-04786-y] [Reference Citation Analysis]
37 Lee EJ, Seshadri M, Bussel JB. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists. Am J Hematol 2021;96:E373-6. [PMID: 34152624 DOI: 10.1002/ajh.26277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]